Wall Street Analysts Remain Cautious on Moderna Stock Despite Recent Gains
Moderna (NASDAQ: MRNA) has seen significant gains in recent months, driven by positive late-stage clinical trial results for its mRNA-based cancer vaccine developed with Merck. The Phase 3 INTerpath-001 trial showed improvements in recurrence-free and distant metastasis-free survival among melanoma patients treated with the combination therapy of Instimeran Autogene and Keytruda. Despite these developments, most Wall Street analysts have maintained a neutral or
Topics: cancer vaccine clinical trials Moderna mRNA technology